Biontech to close three factories in Germany – 1,800 employees affected

BioNTech plans to close three plants by 2028, affecting 1,800 employees. The closures follow failed sales due to market conditions. The company cites low capacity utilization and a focus on cancer medicine. BioNTech reported a net loss of €1.35 billion in the first half of 2023. Co-founders Sahin and Türeci will leave to form a new company, Arife.

BioNTech will close sites in Germany and Singapore after failing to find buyers. The move affects up to 1,860 jobs and is part of a shift in COVID-19 vaccine production to Pfizer. The company stated that socially responsible solutions and redundancy terms have been agreed upon for affected staff.

BioNTech's stock has fallen 63.3% over 5 years, raising questions about its valuation. Recent Phase 3 lung cancer trial data showed promising results, potentially boosting long-term revenue expectations. The company trades at 8.3x P/S, lower than peers. Analysts are divided on whether the oncology pipeline justifies the current valuation, with bulls seeing 16% undervaluation and bears citing 18% overvaluation due to declining COVID-19 vaccine demand.

Pfizer (PFE) and BioNTech (BNTX) received FDA approval for their updated COVID-19 vaccine, COMIRNATY XFG, targeting the XFG variant. The approval secures their position in seasonal COVID-19 immunizations, providing a stable revenue stream. For Pfizer, this supports cash flow and pipeline investments, while for BioNTech, it validates its mRNA platform and maintains market share. Both companies face risks from potential demand declines and market contraction.

BioNTech (BNTX) reported mixed clinical trial results. Its colorectal cancer vaccine, autogene cevumeran, failed in a Phase 2 trial, causing a 10% stock drop. However, its lung cancer treatment, Gotistobart, showed promising early Phase 3 results with a median overall survival of 18.5 months. The company's future depends on upcoming clinical trials, including BNT113 for head and neck cancer, which has received FDA Fast Track designation.

BMO Capital Markets downgraded BioNTech (BNTX) from 'outperform' to 'market perform', lowering its price target from $128 to $105. The downgrade follows a canceled Phase 2 trial for a cancer vaccine and reduced revenue guidance. BioNTech's market cap is around $24B, with $19B in cash and investments, and it has 25+ ongoing cancer therapy trials.